dr. neelapu on interim results of the phase ii zuma-1 study in dlbcl
Published 7 years ago • 90 plays • Length 1:34
Download video MP4
Download video MP3
Similar videos
-
1:18
sattva neelapu, md, tells us about the results of the zuma-1 study in dlbcl presented at ash 2019
-
1:03
sattva neelapu, md, discusses the results of the zuma-1 pivotal phase 2 study with kte-c19
-
1:17
sattva neelapu, md, explains what the results of zuma-1 mean to dlbcl patients
-
1:13
dr. neelapu on primary results of the zuma-1 trial in nhl
-
2:24
dr. neelapu on axi-cel in the zuma-1 trial for refractory aggressive non-hodgkin lymphoma
-
1:23
sattva neelapu, md, discusses efficacy results of the zuma-1 trial
-
1:16
dr. neelapu on zuma-1 trial design of kte-c19
-
2:02
dr. neelapu on updated zuma-1 findings in non-hodgkin lymphoma
-
1:41
sattva neelapu, md, regarding the zuma-1 two-year follow-up study in dlbcl
-
0:32
sattva neelapu, md shares safety results of the zuma-1 trial in patients with nhl
-
1:18
dr. neelapu on the safety profile of kte-c19 in patients with lymphoma
-
8:01
high-risk lymphoma: the zuma-1 and scholar-1 trials
-
0:53
dr. neelapu on next steps with kte-c19 in lymphoma
-
3:48
sattva neelapu, md, discusses details of the zuma-12 trial presented at ash 2020
-
2:32
zuma-1 update: durable survival in r/r dlbcl patients treated with axi-cel
-
2:00
long-term follow-up results of the zuma-1 trial of anti-cd19 car t-cells for non-hodgkin lymphoma
-
3:55
zuma-12: axicabtagene ciloleucel for high-risk large b cell lymphoma
-
0:46
key takeaway from 2-year follow-up data of zuma-1 trial in large b-cell lymphoma
-
2:06
zuma-12: axi-cel as first-line therapy in high-risk large b-cell lymphoma
Clip.africa.com - Privacy-policy